

Application No. 10/607,752
Attorney Docket: 11000.1042c3
Response to Office Action mailed November 4, 2005

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5 (cancelled).

Claim 6 (withdrawn): A genetic construct comprising at least one polynucleotide according to any one of claims 3-5.

Claim 7 (withdrawn): The genetic construct of claim 6, wherein the construct comprises a sequence selected from the group consisting of SEQ ID NO: 56-58 and 82-89.

Claim 8 (withdrawn): A host cell transformed with a genetic construct according to any one of claims 6 and 7.

Claims 9 and 10 (cancelled).

Claim 11 (withdrawn): A polynucleotide encoding a fusion protein of claim 9, wherein the polynucleotide comprises a sequence selected from the group consisting of: SEQ ID NO: 56-58, 82-89 and 115.

Claim 12 (cancelled).

Claim 13 (withdrawn): A composition comprising at least one polynucleotide according to any one of claims 3-5 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

Claim 14 (previously presented): A composition comprising at least one fusion protein according to claim 24 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

Application No. 10/607,752
Attorney Docket: 11000.1042c3
Response to Office Action mailed November 4, 2005

Claim 15 (original): The composition of claim 14, wherein the composition further comprises a flt3 ligand.

Claim 16 (withdrawn): A composition comprising at least one genetic construct according to claim 6, and at least one component selected from the group consisting of physiologically acceptable carriers and immunostimulants.

Claim 17 (currently amended): A method for enhancing an immune response in a patient, comprising administering to the patient a composition according to any one of claims ~~14, 15, 26 and 27~~ 14 and 15.

Claim 18 (original): The method of claim 17, wherein the immune response is a Th1 response.

Claim 19 (original): The method of claim 17, wherein the composition activates at least one cell selected from the group consisting of T cells and NK cells.

Claim 20 (original): The method of claim 17, wherein the composition stimulates cytokine production.

Claim 21 (original): The method of claim 17, wherein the composition induces long-term memory cells.

Claim 22 (currently amended): A method for the treatment of a disorder selected from the group consisting of immune disorders; and infectious diseases and cancer in a patient, comprising administering to the patient a composition according to any one of claims ~~14, 15, 26 and 27~~ 14 and 15.

Application No. 10/607,752
Attorney Docket: 11000.1042c3
Response to Office Action mailed November 4, 2005

Claim 23 (currently amended): A method for the treatment of a disorder in a patient, comprising administering to the patient a composition according to any one of claims 14, 15, 26 and 27 14 and 15, wherein the disorder is tuberculosis.

Claim 24 (previously presented): A fusion protein comprising SEQ ID NO: 116.

Claim 25 (previously presented): A fusion protein comprising a sequence having at least 95% identity to SEQ ID NO: 116, wherein the fusion protein possesses at least one property selected from the group consisting of:

- (a) an ability to stimulate proliferation of T cells from individuals exposed to *Mycobacterium tuberculosis*; and
- (b) an ability to stimulate interferon-gamma secretion from T cells from individuals exposed to *Mycobacterium tuberculosis*.

Claim 26 (previously presented): A composition comprising at least one fusion protein according to claim 25 and at least one component selected from the group consisting of: physiologically acceptable carriers and immunostimulants.

Claim 27 (previously presented): The composition of claim 26, wherein the composition further comprises a flt3 ligand.

Claim 28 (currently amended): [A] The fusion protein encoded by the polynucleotide sequence of SEQ ID NO: 115.

Claim 29 (new): A method for enhancing an immune response in a patient, comprising administering to the patient a composition according to any one of claims 26 and 27.

Claim 30 (new): A method for the treatment of a disorder selected from the group consisting of immune disorders and infectious diseases in a patient, comprising administering to the patient a composition according to any one of claims 26 and 27.

Application No. 10/607,752
Attorney Docket: 11000.1042c3
Response to Office Action mailed November 4, 2005

Claim 31 (new): A method for the treatment of a disorder in a patient, comprising administering to the patient a composition according to any one of claims 26 and 27, wherein the disorder is tuberculosis.